The report provides an in-depth analysis of regional data and an accurate projection of the market size and share of the Top 10 market players across the globe.

Market Scenario:
The global Antifungal Treatment Market is expected to grow at a CAGR of 4.61% during the forecast period and is estimated to reach USD 19,558.0 million by 2023.

Fungal infections such as athlete's foot, ringworm infection, serious systemic infections, and others are spreading rapidly across the globe and a number of treatments are available to treat these diseases. Rising incidence of immunological disease and availability of a wide range of products have driven the growth of the global antifungal treatment market. Furthermore, rising awareness about side effects of traditional drugs and availability of new drugs favor the growth of the market.
Get Sample copy @ https://www.marketresearchfuture.com/sample_request/1628

Key Findings:

Azoles segment in drug class held the largest market share in 2016, which was valued at USD 2,312.6 million in 2016
Systemic segment in therapeutics indication held the largest market share in 2016.
Asia Pacific region is expected to be the fastest growing market at the CAGR of 4.88% during the forecasted period.
Key Players in the Global Antifungal Treatment Market:

Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), Merck & Co., Inc. (U.S), Astellas (Japan), Bayer AG (Germany)

Segments:
The Global Antifungal Treatment Market has been segmented on the basis of drugs class, which includes azoles, pyrimidines, echinocandins, polyenes, allylamines, and others drugs.

On the basis of therapeutic indication, the market is segmented into systemic, candidiasis, coccidioidomycosis, and cryptococcosis.

On the basis of pathogen, the market is segmented into Candida, Aspergillus, Cryptococcus, Coccidioides immitis, Zygomycetes, Trichophyton, and others.

On the basis of end users, the market is segmented into hospitals & clinics, dermatology clinics and other users.

Regional Analysis of Global Antifungal Treatment Market:
Considering the global scenario of the market, the Americas accounted for a significant market share in 2016, which was valued at USD 5,539.4 million as a result of increasing prevalence of immunological diseases and rising healthcare expenditure.

Europe is the second largest market and holds a noticeable share in the global antifungal treatment market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities, skilled medical professionals, and adoption of new therapies.

Increasing prevalence of HIV in Asia Pacific region is the key factor for the market growth. Rising awareness about the antifungal treatment and availability of new treatment methods drive the market in Asia Pacific region. In Asia Pacific, the market shows growth opportunities in China and India. China is expected to be the fastest growing market with the CAGR of 5.24% during the forecasted period.

The Middle East & Africa is expected to show the least growth in this market due to some major factors such as lack of awareness about the anti-fungal treatment, limited access and availability of treatment facilities, low income etc.

Browse Full Reports @ https://www.marketresearchfuture.com/reports/antifungal-treatment-market-1628